Samsung Bioepis announces phase 3 results of SB8, Bevacizumab biosimilar candidate, at ESMO 2019 Congress

Image: Samsung Bioepis announces phase 3 results of SB8, Bevacizumab Biosimilar Candidate, at ESMO 2019 Congress. Photo: courtesy of Colin Behrens from Pixabay.